CD24作为肝细胞癌的新型放射性药物靶点
本研究评估CD24作为肝细胞癌(HCC)免疫PET靶点的可行性。方法包括检测多种HCC细胞系CD24表达,构建CD24敲除的等基因细胞系作为对照,合成[89Zr]Zr-DFO-α-hCD24示踪剂,并在异种移植瘤模型中行PET/CT成像与生物分布研究。结果证实该示踪剂在CD24+肿瘤中特异性摄取高,CD24-肿瘤中摄取低。
要点
- CD24在多种HCC细胞系中高表达,可作为HCC选择性分子靶点
- [89Zr]Zr-DFO-α-hCD24在CD24+ Hep3B肿瘤中摄取为8.7 ± 1.2 %IA/g,CD24-肿瘤为2.3 ± 0.6 %IA/g(注射后144小时)
- 作者认为CD24是有前景的HCC放射诊疗靶点,未来将优化示踪剂以改善肿瘤-肝脏信号比并推动靶向放射药物治疗
核心结论
- 本研究结果确立CD24作为肝细胞癌(HCC)有前景的放射诊疗靶点。
- 未来工作将优化[89Zr]Zr-DFO-α-hCD24以改善肿瘤-肝脏信号比,并促进CD24靶向放射性药物治疗。
研究设计与样本
- 研究评估了CD24在4种HCC细胞系(Huh7、Hep3B、SNU182、SNU449)、1种肝母细胞瘤细胞系(HepG2)和1种CD24+结直肠癌阳性对照细胞系(HT29)中的表达。
- 在SNU449、Hep3B和HT29细胞中通过CRISPR/Cas9介导CD24基因敲除,获得CD24-等基因对照细胞系。
- 合成免疫PET示踪剂[89Zr]Zr-DFO-α-hCD24,并在无胸腺裸鼠的CD24+与CD24-等基因HCC及HT29异种移植瘤模型中行PET/CT成像和离体生物分布评估。
主要发现
- Huh7、Hep3B、SNU449和HT29细胞系显示CD24总蛋白和质膜表达高。
- α-hCD24抗体与重组人CD24结合亲和力好(解离常数2.4 nM),DFO偶联后不受影响(解离常数2.7 nM)。
- [89Zr]Zr-DFO-α-hCD24以高放射化学产率(75% ± 5%)和放射化学纯度(99% ± 1%)高效制备。
- PET/CT成像和生物分布研究证实[89Zr]Zr-DFO-α-hCD24在Hep3B CD24+肿瘤中特异性摄取(注射后144小时为8.7 ± 1.2 %IA/g),在Hep3B CD24-肿瘤中蓄积低得多(2.3 ± 0.6 %IA/g)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. After the use of liver-directed therapies, it is challenging to differentiate between nonviable tumor and viable residual or recurrent disease using conventional imaging techniques. Targeted radiopharmaceutical imaging agents with specificity for HCC-selective molecules may address this unmet need. CD24, a glycosylated plasma membrane protein, is overexpressed in HCC. Here, we describe a CD24-targeted antibody-based PET (immuno-PET) tracer for the noninvasive detection of CD24-positive (CD24+) tumors. Methods: CD24 expression was assessed at the messenger RNA, total protein, and cell membrane levels across 4 HCC cell lines (Huh7, Hep3B, SNU182, SNU449), 1 hepatoblastoma line (HepG2), and a CD24+ colorectal cancer-positive control line (HT29) using quantitative reverse transcription polymerase chain reaction, Western blot testing, and flow cytometry. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9-mediated CD24 gene knockout was performed in SNU449, Hep3B, and HT29 cells to yield otherwise isogenic cell lines as CD24-negative (CD24-) controls. The binding affinity of a humanized monoclonal anti-CD24 antibody (α-hCD24) for recombinant CD24 protein was confirmed by biolayer interferometry and enzyme-linked immunosorbent assay. We then synthesized the immuno-PET tracer ([89Zr]Zr-desferrioxamine [DFO]-α-hCD24) and assessed target engagement in vivo using PET/CT imaging and ex vivo by evaluating the biodistribution of xenograft models using paired CD24+ and CD24- HCC and HT29 isogenic cell lines in athymic nude mice. Results: Huh7, Hep3B, SNU449, and HT29 cell lines demonstrated high total and plasma membrane expression of CD24. The α-hCD24 antibody exhibited good binding affinity to recombinant human CD24 (dissociation constant, 2.4 nM) and was unaffected by DFO conjugation of α-hCD24 (dissociation constant, 2.7 nM). [89Zr]Zr-DFO-α-hCD24 was efficiently produced at high radiochemical yield (75% ± 5%) and radiopurity (99% ± 1%). PET/CT imaging and biodistribution studies confirmed specific uptake of [89Zr]Zr-DFO-α-hCD24 in Hep3B CD24+ tumors (8.7 ± 1.2 %IA/g) and much lower accumulation in Hep3B CD24- tumors (2.3 ± 0.6 %IA/g) at 144 h after injection. Conclusion: Our findings establish CD24 as a promising radiotheranostic target for HCC. Future work will optimize [89Zr]Zr-DFO-α-hCD24 to improve tumor-to-liver signal and facilitate CD24-targeted radiopharmaceutical therapy.
引用
- Makala H, Sheehan-Klenk J, Lee W, et al. CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma. J Nucl Med. 2025. PMID: 40744694. doi:10.2967/jnumed.125.270167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。